These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 25265251

  • 1. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V, Röttgen R, Collettini F, Rothe J, Hamm B, Brenner W, Schreiter N.
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [Abstract] [Full Text] [Related]

  • 2. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V, Röttgen R, Collettini F, Rothe J, Hamm B, Brenner W, Schreiter NF.
    Q J Nucl Med Mol Imaging; 2014 Jan 02. PubMed ID: 24382374
    [Abstract] [Full Text] [Related]

  • 3. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T, Tatsumi M, Onishi H, Nakamoto A, Kim T, Hori M, Sakane M, Hori Y, Morii E, Hatazawa J, Tomiyama N.
    Invest Radiol; 2014 Aug 02; 49(8):524-31. PubMed ID: 24637584
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC, Beer AJ, Souvatzoglou M, Eiber M, Fürst S, Ziegler SI, Brohl F, Schwaiger M, Scheidhauer K.
    Invest Radiol; 2013 May 02; 48(5):263-72. PubMed ID: 23385399
    [Abstract] [Full Text] [Related]

  • 5. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H.
    Neuroendocrinology; 2010 May 02; 91(1):101-9. PubMed ID: 19996582
    [Abstract] [Full Text] [Related]

  • 6. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug 02; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 7. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May 02; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 8. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
    Giesel FL, Kratochwil C, Mehndiratta A, Wulfert S, Moltz JH, Zechmann CM, Kauczor HU, Haberkorn U, Ley S.
    Eur J Radiol; 2012 Oct 02; 81(10):2820-5. PubMed ID: 22236704
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.
    Invest Radiol; 2014 Jan 02; 49(1):7-14. PubMed ID: 24002080
    [Abstract] [Full Text] [Related]

  • 10. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V, Tiling N, Denecke T, Brenner W, Plöckinger U.
    Eur J Nucl Med Mol Imaging; 2016 Oct 02; 43(11):2014-20. PubMed ID: 27293206
    [Abstract] [Full Text] [Related]

  • 11. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol.
    Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, Denecke T, Pavel M, Pascher A, Wiedenmann B, Amthauer H.
    J Nucl Med; 2011 May 02; 52(5):697-704. PubMed ID: 21498531
    [Abstract] [Full Text] [Related]

  • 12. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    J Nucl Med; 2011 Dec 02; 52(12):1864-70. PubMed ID: 22072704
    [Abstract] [Full Text] [Related]

  • 13. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL, Stefanova M, Schwartz LH, Afshar-Oromieh A, Eisenhut M, Haberkorn U, Kratochwil C.
    Q J Nucl Med Mol Imaging; 2013 Jun 02; 57(2):171-6. PubMed ID: 23370092
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic performance of a whole-body dynamic 68GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor.
    Thuillier P, Bourhis D, Karakatsanis N, Schick U, Metges JP, Salaun PY, Kerlan V, Abgral R.
    Medicine (Baltimore); 2020 Aug 14; 99(33):e20021. PubMed ID: 32871968
    [Abstract] [Full Text] [Related]

  • 15. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
    Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.
    J Nucl Med; 2018 Jun 14; 59(6):915-921. PubMed ID: 29191855
    [Abstract] [Full Text] [Related]

  • 16. [Detection of a neuroendocrine differentiated cystic pancreatic lesion by gallium-68-DOTATOC-PET/CT with inconclusive MRI, CT and ultrasound diagnosis].
    Fröling V, Denecke T, Pöllinger A, Schreiter NF.
    Rofo; 2010 Feb 14; 182(2):175-7. PubMed ID: 19998214
    [No Abstract] [Full Text] [Related]

  • 17. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Apr 14; 40(4):514-23. PubMed ID: 23291643
    [Abstract] [Full Text] [Related]

  • 18. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W, Hartmann H, Wiedemann B, Zöphel K, Luboldt HJ.
    Mol Imaging; 2010 Dec 14; 9(6):351-8. PubMed ID: 21084031
    [Abstract] [Full Text] [Related]

  • 19. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE.
    Ann Surg; 2010 Nov 14; 252(5):850-6. PubMed ID: 21037441
    [Abstract] [Full Text] [Related]

  • 20. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A.
    Eur Radiol; 2011 Nov 14; 21(11):2408-16. PubMed ID: 21750886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.